Top

Published in:

01-12-2014 | Letter to the editor

With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed

Authors: Yuko Sugiura, Yoshihiko Soga, Ichiro Tanimoto, Susumu Kokeguchi, Sachiko Morishige-Nishide, Kotoe Itami-Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Kokoro Yamabe, Soichiro Tsutani, Fusanori Nishimura, Shogo Takashiba

Published in: Supportive Care in Cancer | Issue 12/2014

Excerpt

To the editor, …

Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 14:319–326. doi:10.1111/j.1365-2354.2005.00587.x CrossRef

Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424. doi:10.1007/s00520-007-0391-z PubMedCrossRef

Sugiura Y, Soga Y, Yamabe K, Tsutani S, Tanimoto I, Maeda H, Kokeguchi S, Fujii N, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S (2010) Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. Support Care Cancer 18:395–398. doi:10.1007/s00520-009-0789-x PubMedCrossRef

Warde P, Kroll B, O’Sullivan B, Aslanidis J, Tew-George E, Waldron J, Maxymiw W, Liu FF, Payne D, Cummings B (2000) A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 8:203–208PubMedCrossRef

Title: With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed
Authors: Yuko Sugiura
Yoshihiko Soga
Ichiro Tanimoto
Susumu Kokeguchi
Sachiko Morishige-Nishide
Kotoe Itami-Kono
Kanayo Takahashi
Nobuharu Fujii
Fumihiko Ishimaru
Mitsune Tanimoto
Kokoro Yamabe
Soichiro Tsutani
Fusanori Nishimura
Shogo Takashiba
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 12/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2432-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2014

Which quality of life instruments are preferred by cancer patients in Japan? Comparison of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and the Functional Assessment of Cancer Therapy-General

Returning to work following curative chemotherapy: a qualitative study of return to work barriers and preferences for intervention

Improving communication in cancer pain management nursing: a randomized controlled study assessing the efficacy of a communication skills training program

The dyadic effects of coping and resilience on psychological distress for cancer survivor couples

Developing a palliative care service model for Muslim Middle Eastern countries

A comprehensive assessment protocol including patient reported outcomes, physical tests, and biological sampling in newly diagnosed patients with head and neck cancer: is it feasible?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer